Waldenström macroglobulinemia

Béla Telek, Péter Batár, László Váróczy, L. Gergely, László Rejto, Róbert Szász, Zsófia Miltényi, Zsófia Simon, M. Udvardy, A. Illés

Research output: Contribution to journalArticle

Abstract

Waldenström macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974.

Original languageEnglish
Pages (from-to)1970-1974
Number of pages5
JournalOrvosi Hetilap
Volume154
Issue number50
DOIs
Publication statusPublished - Dec 1 2013

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
B-Lymphocytes
Bone Marrow
Alkylating Agents
Stem Cell Transplantation
Rare Diseases
Serum
Electrophoresis
Anemia
Proteins
Therapeutics
Rituximab
purine
Bortezomib

Keywords

  • Chemoimmunotherapy
  • Fludarabine
  • Lymphoplasmacytic cells
  • Monoclonal IgM protein
  • Rituximab
  • Stem-cell transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Telek, B., Batár, P., Váróczy, L., Gergely, L., Rejto, L., Szász, R., ... Illés, A. (2013). Waldenström macroglobulinemia. Orvosi Hetilap, 154(50), 1970-1974. https://doi.org/10.1556/OH.2013.29776

Waldenström macroglobulinemia. / Telek, Béla; Batár, Péter; Váróczy, László; Gergely, L.; Rejto, László; Szász, Róbert; Miltényi, Zsófia; Simon, Zsófia; Udvardy, M.; Illés, A.

In: Orvosi Hetilap, Vol. 154, No. 50, 01.12.2013, p. 1970-1974.

Research output: Contribution to journalArticle

Telek, B, Batár, P, Váróczy, L, Gergely, L, Rejto, L, Szász, R, Miltényi, Z, Simon, Z, Udvardy, M & Illés, A 2013, 'Waldenström macroglobulinemia', Orvosi Hetilap, vol. 154, no. 50, pp. 1970-1974. https://doi.org/10.1556/OH.2013.29776
Telek B, Batár P, Váróczy L, Gergely L, Rejto L, Szász R et al. Waldenström macroglobulinemia. Orvosi Hetilap. 2013 Dec 1;154(50):1970-1974. https://doi.org/10.1556/OH.2013.29776
Telek, Béla ; Batár, Péter ; Váróczy, László ; Gergely, L. ; Rejto, László ; Szász, Róbert ; Miltényi, Zsófia ; Simon, Zsófia ; Udvardy, M. ; Illés, A. / Waldenström macroglobulinemia. In: Orvosi Hetilap. 2013 ; Vol. 154, No. 50. pp. 1970-1974.
@article{e81281a278224604af165b4194ed73be,
title = "Waldenstr{\"o}m macroglobulinemia",
abstract = "Waldenstr{\"o}m macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974.",
keywords = "Chemoimmunotherapy, Fludarabine, Lymphoplasmacytic cells, Monoclonal IgM protein, Rituximab, Stem-cell transplantation",
author = "B{\'e}la Telek and P{\'e}ter Bat{\'a}r and L{\'a}szl{\'o} V{\'a}r{\'o}czy and L. Gergely and L{\'a}szl{\'o} Rejto and R{\'o}bert Sz{\'a}sz and Zs{\'o}fia Milt{\'e}nyi and Zs{\'o}fia Simon and M. Udvardy and A. Ill{\'e}s",
year = "2013",
month = "12",
day = "1",
doi = "10.1556/OH.2013.29776",
language = "English",
volume = "154",
pages = "1970--1974",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "50",

}

TY - JOUR

T1 - Waldenström macroglobulinemia

AU - Telek, Béla

AU - Batár, Péter

AU - Váróczy, László

AU - Gergely, L.

AU - Rejto, László

AU - Szász, Róbert

AU - Miltényi, Zsófia

AU - Simon, Zsófia

AU - Udvardy, M.

AU - Illés, A.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Waldenström macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974.

AB - Waldenström macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974.

KW - Chemoimmunotherapy

KW - Fludarabine

KW - Lymphoplasmacytic cells

KW - Monoclonal IgM protein

KW - Rituximab

KW - Stem-cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84890258849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890258849&partnerID=8YFLogxK

U2 - 10.1556/OH.2013.29776

DO - 10.1556/OH.2013.29776

M3 - Article

C2 - 24317355

AN - SCOPUS:84890258849

VL - 154

SP - 1970

EP - 1974

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 50

ER -